Explore All 14 Sold to Existing Investors Media Deals - Search the Database Free
Investment Summary |
|
|---|---|
| Date | January 5, 2000 |
| Target | Channel 5 Broadcasting |
| Sector | Media |
| Sellers(s) | Warburg Pincus |
| Deal Type | Sold to Existing Investors |
FILTER BY
| Category | Private Equity Firm |
|---|---|
| Founded | 1966 |
| PE ASSETS | 83.0B USD |
| Size | Mega |
| Type | Sector Agnostic |
Warburg Pincus is a mega-sized, global private equity firm focused on investment opportunities across North America, Asia, and Europe. Warburg will consider investing at various company stages, from early-stage opportunities to distressed situations. Warburg Pincus is organized by industry groups. Verticals include financial services, healthcare, technology, media & telecommunications, energy, consumer & industrial, and real estate. Within financial services, Warburg will consider asset/wealth managers, banks, exchanges, financial technology, insurance, transaction processing, private banking, and specialty/consumer finance. Within healthcare, specific areas of interest include medical devices, healthcare services, and biotech/pharmaceuticals. Within technology/media/communications, Warburg targets software, media/internet/information, financial technology, telecom, business services, and systems/semiconductors. Within energy, specific areas of interest include oil/gas exploration, power generation/transmission, and alternative energy. Warburg Pincus raised its first fund in 1966 and is based in New York City.
| Deal Context for Seller | # |
|---|---|
| Overall | 7 of 265 |
| Sector: Media | 1 of 4 |
| Type: Sold to Existing Investors | 1 of 2 |
| Country: United Kingdom | 2 of 17 |
| Year: 2000 | 1 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2000-01-01 |
ZymoGenetics
Seattle, Washington, United States ZymoGenetics, Inc. is a biopharmaceutical company focused on the discovery and development of protein therapeutics that prevent or treat significant human diseases. The company launched its first product on the U.S. market in 2008 and has a strong pipeline of additional products in development. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2000-01-10 |
InterMune
Brisbane, California, United States InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, the company is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive, irreversible, unpredictable and ultimately fatal lung disease. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. |
Buy | - |
